Innovations for screening and prognosis in HIV+ cancers including Kaposi sarcoma, cervical cancer, and lymphoma in Malawi and South Africa

马拉维和南非的艾滋病毒癌症筛查和预后创新，包括卡波西肉瘤、宫颈癌和淋巴瘤

• 批准号: 10652369
• 负责人: Carla J Chibwesha
• 金额: $ 109.71万
• 依托单位: UNIV OF NORTH CAROLINA CHAPEL HILL
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-08-13 至 2025-07-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10652369
• 关键词: AIDS Malignancy Consortium; AIDS clinical trial group; AIDS related cancer; AIDS-Related Lymphoma; Achievement; Acquired Immunodeficiency Syndrome; Address; Africa; Africa South of the Sahara; Basic Science; Biological Markers; Cancer Burden; Cancer Control; Cancer Prognosis; Caring; Clinical Research; Clinical Sciences; Clinical Trials; Collaborations; Communicable Diseases; Communities; Comprehensive Cancer Center; Crystallization; Data; Ensure; Epidemic; Flowers; Goals; HIV; HIV/AIDS; Health; Hospitals; Individual; Infrastructure; Institution; International; Kaposi Sarcoma; Knowledge; Leadership; Lymphoma; Malawi; Malignant Neoplasms; Malignant neoplasm of cervix uteri; Medicine; Molecular; North Carolina; Patients; Persons; Policies; Population Sciences; Positioning Attribute; Principal Investigator; Prognosis; Qualifying; Recurrence; Research; Research Infrastructure; Research Personnel; Research Priority; Research Project Grants; Science; Site; South Africa; South African; Survival Rate; Training; Training and Infrastructure; Translational Research; Trust; UNC Lineberger Comprehensive Cancer Center; United States National Institutes of Health; Universities; anticancer research; antiretroviral therapy; career; clinical research site; college; combat; comorbidity; data sharing; detection method; epidemiology study; global health; high risk; improved; innovation; insight; low and middle-income countries; next generation; oncology program; programs; progression risk; response; screening; success; translational impact; tumor

ABSTRACT: OVERALL COMPONENT: Innovations for screening and prognosis in HIV+ cancers including Kaposi sarcoma, cervical cancer, and lymphoma in Malawi and South Africa In response to RFA-CA-20-001, this application proposes to establish the UNC-Malawi-South Africa Cancer Consortium (UMSACC), to develop capacity and conduct high-impact research focused on HIV-associated cancers. The consortium builds on longstanding collaborations between the University of North Carolina at Chapel Hill, Lighthouse Trust in Malawi, Malawi Ministry of Health, Malawi College of Medicine, the University of the Witwatersrand, South Africa, and Stellenbosch University, South Africa. These partnerships have been made possible by leadership and participation in NIH networks conducting basic, clinical and epidemiologic research in the region. These existing relationships and robust infrastructure can now be leveraged for HIV- associated malignancies, which are overwhelming contributors to cancer burden in Malawi and South Africa even after widespread antiretroviral therapy usage. UMSACC is focused on the three most common HIV- associated cancers, Kaposi sarcoma (KS), cervical cancer, and lymphoma, and addresses the NIH HIV/AIDS research priorities by focusing on HIV-associated comorbidities which includes these AIDS-defining cancers. UMSACC proposes innovations for screening and prognosis of these cancers in persons living with HIV (PLWH) with the overall goal being to improve the health of PLWH. Our consortium will be led by principal investigators with highly complementary expertise using a team science approach. To support consortium objectives, a diverse team of investigators has been assembled spanning the clinical, population, and basic sciences, and includes Malawian, South African, and US scientific leaders. Moreover, a high priority is the training and support of junior investigators in the U.S. and Africa. The consortium will enhance existing administrative, operational, and research relationships between all partnering institutions and investigators. The External Advisory Board and Scientific Advisors will ensure that the consortium remains highly responsive to community needs in Malawi and South Africa, while also addressing urgent research questions facing the international HIV-associated cancer community. A focus of this consortium is to develop Malawi and South Africa to become international leaders in HIV- associated cancer research. Building on prior successes and partnerships outlined in this application, UMSACC is extremely well-positioned to catalyze a broad, coordinated, cancer control effort in Malawi and South Africa, and to advance the overall NCI scientific agenda for sub-Saharan Africa to reduce HIV- associated cancer burden in low- and middle-income countries.

摘要：总体组成部分：HIV+癌症筛查和预后的创新